Compare Bristol-Myers Squibb Co (BMY) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Linde PLC — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Linde PLC trades at $490.38 (market cap $226.12B). The key difference: Linde PLC is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | LIN | |
|---|---|---|
Market Cap | $129.94B | $226.12B |
Sector | Health | Basic Materials |
52-Week High | $65.89 | $546.64 |
52-Week Low | $42.60 | $389.38 |
Enterprise Value | $163.92B | $249.24B |
Dividend Yield | 3.96% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Linde (LIN) trades at $492.46, up 0.51% on the day, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $4.50 exceeding the $4.49 estimate (Zacks Investment Research, 2026-05-01). Revenue growth is steady, and profitability remains robust with a 20.43% net income margin. Analyst sentiment is overwhelmingly positive, with a consensus price target of $553.60.
The outlook for LIN is favorable due to its operational strength and dividend growth, though valuation multiples are elevated. Key risks include rising debt levels and macroeconomic pressures on industrial demand. The stock offers a compelling opportunity for long-term investors seeking quality industrial exposure, but near-term technical weakness may present entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
